# +RNAinsight

Find More Answers with Paired DNA and RNA Testing



# Better Variant Detection & Classification

Paired DNA/RNA genetic testing with +RNAinsight analyzes functional RNA data to help detect and classify DNA variants, including deep intronic mutations. Deep intronic mutations may be missed with a DNA-only or reflexive RNA testing approach. As a result, diagnostic yield is higher and variant of uncertain significance rate is lower, providing clarity for patients and healthcare providers.<sup>1</sup> This novel functional evidence is especially important in non-White populations that have been underrepresented in research and clinical testing.

## **1-90 Genes**

## For Maximum Flexibility

Order +RNAinsight with analysis of any genes on the hereditary cancer menu<sup>\*\*</sup>

**5%** 

#### Hereditary Cancer Cases Leverage RNA Data

RNA data can benefit all Ambry patients, even those with DNA-only testing<sup>1</sup>

## 1/25 Positive Patients Would

## Be Missed Without RNA

Results without +RNAinsight would be negative or inconclusive<sup>2</sup> ~6%

## **Reduction in VUS Rate**

+RNAinsight reduces ambiguity for providers and patients


## 12,000 Non-White Patients Have Benefited

+RNAinsight provided functional data to address known data gaps



## +RNAinsight<sup>®</sup> Gene Coverage, Compatibility, and Experience

+RNAinsight can be ordered for up to 90 genes associated with cancers of the breast, ovaries, uterus, prostate, colon, kidneys, pancreas, and more. It can be paired with most" Ambry Genetics hereditary cancer panels to provide functional RNA information to help identify and interpret DNA variants.



#### Experience That Matters

In 2019, Ambry Genetics became the first clinical lab to introduce paired DNA/RNA testing. Since that time, we have performed concurrent DNA and RNA testing on over 800,000 patients and classified over 1,600 unique variants. We've grown our team to more than 30 scientists who analyze and interpret RNA results. To meet our continued commitment to data-sharing and transparency, we've contributed to over 30 scientific posters, presentations, and publications.

## Ambr assi

#### Let us be your trusted partner

All hereditary cancer tests utilize Ambry's Classifi™ program, a proprietary, knowledge-driven engine for gene classification, variant analysis & interpretation, and reporting. The Classifi program delivers the highest quality test results and ensures we leave no stone unturned in getting answers for you and your patients.

\*\* Not available for STAT Testing or BRCAPlus.®

#### **Requires EDTA (DNA) & PAXgene (RNA) Specimens**



## 14-21 Day **Turn Around Time**



### **CAP/CLIA** Certified and **New York State Approved**

Technical Details +RNAinsight analyzes transcripts for up to 90 genes depending which Ambry Genetics DNA-based hereditary cancer panel it is paired with and depending on the absence or presence of RNA transcripts expressed in the blood. The results from +RNAinsight are used to provide functional RNA information to further support detection and classification of DNA variants. It is not intended to be used as a stand-alone diagnostic test.

For More Information CONTACT YOUR AMBRY SALES REP

#### References

1. Horton, C., Hoang, L., Zimmermann, H., Young, C., Grzybowski, J., Durda, K., Vuong, H., Burks, D., Cass, A., LaDuca, H., Richardson, M. E., Harrison, S., Chao, E. C., & amp; Karam, R. (2023) Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. *JAMA Oncology*. https://doi.org/10.1001/jamaaoncol.2023.55862.

2. Horton C, et al. Expanding the reach of paired DNA and RNA sequencing: Results from 450,000 consecutive individuals from a hereditary cancer cohort; (Oral Presentation Session 84 - Strategies to Interpret Germline Variants in Cancer Predispostion Genes). Presented at the Annual Meeting of The American Society of Human Genetics, November 68, 2024, in Denver, CO. \*Based on internal data